UY36537A - Método de uso de la respuesta al anticuerpo antiacetato de glatirámero - Google Patents
Método de uso de la respuesta al anticuerpo antiacetato de glatirámeroInfo
- Publication number
- UY36537A UY36537A UY0001036537A UY36537A UY36537A UY 36537 A UY36537 A UY 36537A UY 0001036537 A UY0001036537 A UY 0001036537A UY 36537 A UY36537 A UY 36537A UY 36537 A UY36537 A UY 36537A
- Authority
- UY
- Uruguay
- Prior art keywords
- glatiramer acetate
- months
- initial dose
- human subject
- month
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Métodos para inducir anticuerpos anti-acetato de glatirámero específicos en un sujeto humano afectado por esclerosis múltiple, que comprende administrar al sujeto humano tres inyecciones subcutáneas de una dosis de 40 mg/ml de acetato de glatirámero por semana durante por lo menos 12 meses, de modo tal que el nivel de anticuerpos anti-GA específicos en la sangre o el suero del sujeto humano i) aumenta durante hasta aproximadamente 6 meses después de administrar una dosis inicial de 40 mg/ml de la administración de acetato de glatirámero al sujeto humano; ii) aumenta a un índice mayor durante el primer mes después de la dosis inicial de 40 mg/ml de acetato de glatirámero en comparación con el índice de aumento después del primer mes al tercer mes después de la dosis inicial de 40 mg/ml de acetato de glatirámero; iii) alcanzan un pico aproximadamente 3 o aproximadamente 6 meses o entre aproximadamente 3 y aproximadamente 6 meses después de la dosis inicial de 40 mg/ml de acetato de glatirámero; y iv) es más alto que el nivel basal por lo menos durante aproximadamente 12 meses después de la dosis inicial de 40 mg/ml de acetato de glatirámero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109033P | 2015-01-28 | 2015-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36537A true UY36537A (es) | 2016-08-31 |
Family
ID=56433699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036537A UY36537A (es) | 2015-01-28 | 2016-01-25 | Método de uso de la respuesta al anticuerpo antiacetato de glatirámero |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160213633A1 (es) |
| AR (1) | AR103461A1 (es) |
| TW (1) | TW201639591A (es) |
| UY (1) | UY36537A (es) |
| WO (1) | WO2016123344A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003099328A1 (en) * | 2002-05-21 | 2003-12-04 | Mayo Foundation For Medical Education And Research | Methods and materials for treating inflammatory conditions |
| US8394763B2 (en) * | 2007-09-26 | 2013-03-12 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| NZ609938A (en) * | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
-
2015
- 2015-07-15 US US14/800,014 patent/US20160213633A1/en not_active Abandoned
- 2015-12-25 TW TW104143903A patent/TW201639591A/zh unknown
-
2016
- 2016-01-20 AR ARP160100142A patent/AR103461A1/es unknown
- 2016-01-25 UY UY0001036537A patent/UY36537A/es not_active Application Discontinuation
- 2016-01-28 WO PCT/US2016/015369 patent/WO2016123344A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20160213633A1 (en) | 2016-07-28 |
| AR103461A1 (es) | 2017-05-10 |
| WO2016123344A1 (en) | 2016-08-04 |
| TW201639591A (zh) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019065028A5 (es) | ||
| DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| AR099078A2 (es) | Un medicamento que comprende acetato de glatiramer | |
| MX2017005106A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| TR201900649T4 (tr) | Oküler hastalıkların tedavisi için mrna tedavisi. | |
| MX2021012050A (es) | Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad. | |
| Schaap-Fogler et al. | Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis | |
| MX355065B (es) | Método y dispositivo para conmutación de cámaras. | |
| JP2015187125A5 (es) | ||
| BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
| NZ630790A (en) | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes | |
| BR112016012506A2 (pt) | Combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| CL2018000002A1 (es) | Agente terapéutico y método para tratar el síndrome de hunter. | |
| CY1118826T1 (el) | Διαδικασια για την κατασκευη ενος φαρμακευτικου σκευασματος που περιεχει glatiramer acetate | |
| HRP20201388T1 (hr) | Režimi i postupci liječenja multiple skleroze uporabom ofatumumaba | |
| RU2016149316A (ru) | Лечение ревматоидного артрита | |
| MX2017008000A (es) | Sistema de inyeccion de un solo uso. | |
| UY36537A (es) | Método de uso de la respuesta al anticuerpo antiacetato de glatirámero | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| EA202191308A1 (ru) | Одноразовая кассета в сборе | |
| IL274563B1 (en) | Methods of use and preparations containing dolaglutide | |
| BR112017012975A2 (pt) | formulações injetáveis de paracetamol | |
| Kimelman et al. | Pre-Clinical Studies and Evaluation of Treatment Need of Glatiramer Acetate Depot (Long Acting Injection of GA) | |
| BR112022004723A2 (pt) | Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201204 |